Sweden-based Cyxone, a developer of therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders, has engaged a major European contract development and manufacturing organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaborat...